KBC Group NV Buys New Shares in Astrana Health, Inc. (NASDAQ:ASTH)

KBC Group NV bought a new position in shares of Astrana Health, Inc. (NASDAQ:ASTH) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 1,214 shares of the company’s stock, valued at approximately $70,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. GAMMA Investing LLC acquired a new stake in shares of Astrana Health during the 3rd quarter worth approximately $34,000. Nisa Investment Advisors LLC bought a new position in Astrana Health in the third quarter worth $35,000. Central Pacific Bank Trust Division acquired a new stake in Astrana Health during the third quarter worth $160,000. Everence Capital Management Inc. bought a new stake in Astrana Health in the 3rd quarter valued at $272,000. Finally, Granite Bay Wealth Management LLC acquired a new position in shares of Astrana Health in the 3rd quarter valued at $290,000. 52.77% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently weighed in on ASTH. BTIG Research lifted their target price on shares of Astrana Health from $60.00 to $70.00 and gave the company a “buy” rating in a research report on Thursday, October 3rd. Stifel Nicolaus lifted their price objective on Astrana Health from $48.00 to $60.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Robert W. Baird increased their target price on Astrana Health from $67.00 to $86.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Truist Financial boosted their price target on Astrana Health from $50.00 to $59.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Finally, KeyCorp started coverage on Astrana Health in a research note on Friday, October 11th. They set a “sector weight” rating for the company. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Astrana Health currently has an average rating of “Buy” and a consensus price target of $65.17.

Astrana Health Price Performance

NASDAQ ASTH opened at $42.11 on Friday. The stock’s 50 day simple moving average is $54.41 and its 200 day simple moving average is $47.77. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.91. Astrana Health, Inc. has a one year low of $32.32 and a one year high of $63.20. The firm has a market cap of $2.37 billion, a PE ratio of 32.49, a price-to-earnings-growth ratio of 1.90 and a beta of 1.24.

Astrana Health (NASDAQ:ASTH) last announced its earnings results on Thursday, November 7th. The company reported $0.33 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.33. The company had revenue of $478.71 million during the quarter, compared to analyst estimates of $462.01 million. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. During the same period last year, the company posted $0.47 earnings per share. As a group, sell-side analysts forecast that Astrana Health, Inc. will post 1.17 earnings per share for the current fiscal year.

Astrana Health Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.